China’s NMPA approves JW Therapeutics CAR-T cell therapy for mantle cell lymphoma
Carteyva becomes the first cell therapy approved in China for treating patients with relapsed or refractory mantle cell lymphoma.
28 August 2024
28 August 2024
Carteyva becomes the first cell therapy approved in China for treating patients with relapsed or refractory mantle cell lymphoma.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.